These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32513774)

  • 61. Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression.
    Huang TT; Tseng LM; Chen JL; Chu PY; Lee CH; Huang CT; Wang WL; Lau KY; Tseng MF; Chang YY; Chiang TY; Ueng YF; Lee HC; Dai MS; Liu CY
    EBioMedicine; 2020 Apr; 54():102717. PubMed ID: 32268268
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.
    Liu CY; Hu MH; Hsu CJ; Huang CT; Wang DS; Tsai WC; Chen YT; Lee CH; Chu PY; Hsu CC; Chen MH; Shiau CW; Tseng LM; Chen KF
    Oncotarget; 2016 Feb; 7(8):9135-49. PubMed ID: 26824320
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
    Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
    Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
    Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
    J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
    [TBL] [Abstract][Full Text] [Related]  

  • 65. INPP4B overexpression suppresses migration, invasion and angiogenesis of human prostate cancer cells.
    Chen H; Li H; Chen Q
    Clin Exp Pharmacol Physiol; 2017 Jun; 44(6):700-708. PubMed ID: 28261855
    [TBL] [Abstract][Full Text] [Related]  

  • 66. INPP4B: the new kid on the PI3K block.
    Agoulnik IU; Hodgson MC; Bowden WA; Ittmann MM
    Oncotarget; 2011 Apr; 2(4):321-8. PubMed ID: 21487159
    [TBL] [Abstract][Full Text] [Related]  

  • 67. FRET biosensor-based kinase inhibitor screen for ERK and AKT activity reveals differential kinase dependencies for proliferation in TNBC cells.
    He J; Wink S; de Bont H; Le Dévédec S; Zhang Y; van de Water B
    Biochem Pharmacol; 2019 Nov; 169():113640. PubMed ID: 31536726
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Inhibition of Akt/mTOR pathway overcomes intrinsic resistance to dasatinib in triple-negative breast cancer.
    Haga Y; Higashisaka K; Yang L; Sekine N; Lin Y; Tsujino H; Nagano K; Tsutsumi Y
    Biochem Biophys Res Commun; 2020 Dec; 533(4):672-678. PubMed ID: 33036754
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Integrin β1, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer.
    Choi C; Kwon J; Lim S; Helfman DM
    Oncotarget; 2016 Sep; 7(39):63466-63487. PubMed ID: 27563827
    [TBL] [Abstract][Full Text] [Related]  

  • 70. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.
    Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X
    J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797
    [TBL] [Abstract][Full Text] [Related]  

  • 71. IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells.
    Itoh T; Hatano R; Horimoto Y; Yamada T; Song D; Otsuka H; Shirakawa Y; Mastuoka S; Iwao N; Aune TM; Dang NH; Kaneko Y; Okumura K; Morimoto C; Ohnuma K
    Cell Death Dis; 2021 May; 12(6):520. PubMed ID: 34021125
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
    Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
    EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.
    Zawistowski JS; Bevill SM; Goulet DR; Stuhlmiller TJ; Beltran AS; Olivares-Quintero JF; Singh D; Sciaky N; Parker JS; Rashid NU; Chen X; Duncan JS; Whittle MC; Angus SP; Velarde SH; Golitz BT; He X; Santos C; Darr DB; Gallagher K; Graves LM; Perou CM; Carey LA; Earp HS; Johnson GL
    Cancer Discov; 2017 Mar; 7(3):302-321. PubMed ID: 28108460
    [TBL] [Abstract][Full Text] [Related]  

  • 74. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.
    Powell E; Shao J; Yuan Y; Chen HC; Cai S; Echeverria GV; Mistry N; Decker KF; Schlosberg C; Do KA; Edwards JR; Liang H; Piwnica-Worms D; Piwnica-Worms H
    Breast Cancer Res; 2016 Jan; 18(1):13. PubMed ID: 26818199
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Estradiol induces BDNF/TrkB signaling in triple-negative breast cancer to promote brain metastases.
    Contreras-Zárate MJ; Day NL; Ormond DR; Borges VF; Tobet S; Gril B; Steeg PS; Cittelly DM
    Oncogene; 2019 Jun; 38(24):4685-4699. PubMed ID: 30796353
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes.
    Lehmann BD; Pietenpol JA
    J Pathol; 2014 Jan; 232(2):142-50. PubMed ID: 24114677
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
    Kim S; Lee J; Jeon M; Lee JE; Nam SJ
    Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Estrogen receptor β regulates AKT activity through up-regulation of INPP4B and inhibits migration of prostate cancer cell line PC-3.
    Chaurasiya S; Wu W; Strom AM; Warner M; Gustafsson JÅ
    Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26347-26355. PubMed ID: 33020300
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Inositol polyphosphate-4-phosphatase type II and rucaparib treatment inhibit the growth of osteosarcoma cells dependent on phosphoinositide 3-kinase/protein kinase B pathway.
    Li D; Yang J; Ma H; Sun C; Feng R
    J Cell Biochem; 2018 Dec; 119(12):9899-9909. PubMed ID: 30132953
    [TBL] [Abstract][Full Text] [Related]  

  • 80. INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas.
    Chi MN; Guo ST; Wilmott JS; Guo XY; Yan XG; Wang CY; Liu XY; Jin L; Tseng HY; Liu T; Croft A; Hondermarck H; Scolyer RA; Jiang CC; Zhang XD
    Oncotarget; 2015 Nov; 6(37):39891-907. PubMed ID: 26573229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.